Endocrine Abstracts

Introduction: Patients with neuroendocrine tumours located in the gastroenteropancreatic tract (GEP-NETs) and treatment with somatostatin analogues (SSA’s) are at risk of malnutrition which has been reported previously, based on weight loss or body mass index (BMI) only. Since 2019 The Global leadership into malnutrition (GLIM) criteria exist to diagnose malnutrition, including weight loss, BMI and sarcopenia. These GLIM criteria have not been assessed in...

Introduction: Since 2019 the Global Leadership Into Malnutrition (GLIM) criteria exist for diagnosing malnutrition. Patients with gastoenteropancreatic (GEP) neuroendocrine tumours (NETs) using somatostatin analogue’s (SSA’s) are at risk of malnutrition. Deficiencies in fat-soluble vitamins, minerals and trace elements are not part of the GLIM criteria but frequently reported in patients with GEP-NETs using SSA’s. The relationship between malnut...

Introduction: Maintaining adequate nutritional status can be a challenge for patients with small intestinal neuroendocrine tumours (NETs) and mesenteric lymph node metastasis which can form a mesenteric mass. The preferred treatment option would be resection of this mesenteric mass, however, due to adjacent small bowel loops there is a risk of developing short bowel syndrome (SBS). If the mesenteric mass is not resected there is a risk of developing inoperable...